Matthew Lang - Feb 10, 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role: Chief Business Officer
Signature: /s/ Matthew Lang
Stock symbol: LYEL
Transactions as of: Feb 10, 2025
Transactions value $: $0
Form type: 4
Date filed: 2/26/2025, 07:36 PM
Previous filing: Feb 13, 2024
Next filing: Apr 30, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LYEL	Common Stock	Award	$0	+113K	+225%	$0.00	163K	Feb 10, 2025	Direct	F1

Showing 1 to 1 of 1 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LYEL	Option (right to buy)	Award	$0	+450K		$0.00	450K	Feb 10, 2025	Common Stock	450K	$0.55	Direct	F2
transaction	LYEL	Option (right to buy)	Award	$0	+56.3K		$0.00	56.3K	Feb 10, 2025	Common Stock	56.3K	$0.55	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date.
F2	12.5% of the option shares will vest on August 9, 2025, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date.
F3	The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon the achievement of specified performance criteria.